AS3MT — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21856686	1.00	10/20
SCHEMBL5857217	0.62	10/20
SCHEMBL5857144	1.00	9/20
SCHEMBL5857150	1.00	9/20
SCHEMBL5858444	0.72	9/20
SCHEMBL5858449	0.72	9/20
SCHEMBL5857839	0.60	9/20
SCHEMBL5858348	0.87	8/20
SCHEMBL21856750	0.81	8/20
SCHEMBL5857186	0.78	8/20
SCHEMBL5857191	0.78	8/20
SCHEMBL5857288	0.71	8/20
SCHEMBL5857153	0.71	8/20
SCHEMBL5857151	0.65	8/20
SCHEMBL5858337	0.64	8/20
SCHEMBL5858514	0.63	8/20
SCHEMBL5857954	0.58	8/20
SCHEMBL5857105	0.58	8/20
SCHEMBL5857816	0.55	8/20
SCHEMBL5857166	0.54	8/20

Clinical trials — most relevant to AS3MT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic	PHASE4	COMPLETED
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)	PHASE4	COMPLETED
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation	PHASE2	UNKNOWN
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE2	WITHDRAWN
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)	PHASE2	COMPLETED
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations	PHASE2	UNKNOWN
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery	PHASE1/PHASE2	UNKNOWN
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders	PHASE1	COMPLETED
Returning Genetic Results on Arsenic Susceptibility	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Dietary Effects of Sulfur Amino Acids	nan	COMPLETED
Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J	nan	COMPLETED
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans	nan	ACTIVE_NOT_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Analysis of DNA Methylation in Spondyloarthritis	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AS3MT binder may also engage these)

Protein	Name	Similarity
Q8VHT6	—	1.000	Q8VHT6 →
Q91WU5	—	1.000	Q91WU5 →
Q8BJM7	—	0.995	Q8BJM7 →
P27472	—	0.993	P27472 →
Q2KHP8	—	0.993	Q2KHP8 →
Q0DG35	—	0.993	Q0DG35 →
Q12680	—	0.993	Q12680 →
A4SFM6	—	0.993	A4SFM6 →
Q9NV66	—	0.993	Q9NV66 →
KDM5B	Lysine-specific demethylase 5B	0.993	landscape →
Q0JKD0	—	0.993	Q0JKD0 →
B4SU90	—	0.992	B4SU90 →
A8X3V8	—	0.992	A8X3V8 →
Q9T0P4	—	0.992	Q9T0P4 →
P0A7F7	—	0.992	P0A7F7 →
B5YZF5	—	0.992	B5YZF5 →
Q3Z5P0	—	0.992	Q3Z5P0 →
A7ZW69	—	0.992	A7ZW69 →
Q5REF9	—	0.992	Q5REF9 →
Q9STV0	—	0.992	Q9STV0 →
Q2NVS2	—	0.992	Q2NVS2 →
B5X574	—	0.992	B5X574 →
Q03460	—	0.992	Q03460 →
Q8FL39	—	0.992	Q8FL39 →
B7MBA3	—	0.992	B7MBA3 →
Q08960	—	0.992	Q08960 →
B7MNY2	—	0.992	B7MNY2 →
P90986	—	0.992	P90986 →
A1ZB91	—	0.992	A1ZB91 →
Q9LK36	—	0.992	Q9LK36 →